このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Study of ORJ-001 for the Treatment of IPF

2026年11月16日 更新者:Oorja Bio, Inc.

A Phase 2a/2b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Tolerability (Part A), and Efficacy (Part B), of ORJ-001 in Patients With Idiopathic Pulmonary Fibrosis (ORBIT-IPF)

ORJ-001 is a new class of drugs intended for the treatment of patients with idiopathic pulmonary fibrosis (IPF). This is a Phase 2 study in two parts; the objective of Part A will determine if ORJ-001 is well-tolerated by patients and how long the drug stays in the body. Part B will test how well the drug affects lung function. Animal models of IPF have shown that ORJ-001 can repair damaged lung tissue and improve markers of lung function.

調査の概要

状態

募集

詳細な説明

This Phase 2a/2b, randomized, double-blind, placebo-controlled, multicenter study will evaluate the safety, tolerability, and efficacy of ORJ-001 administered subcutaneously twice weekly in adults with IPF. The study consists of two parts. Part A will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of two dose levels of ORJ-001 compared with placebo over 12 weeks of treatment. Data from Part A will be reviewed by an independent Data Monitoring Committee to select the dose for Part B. Participants in Part A will not continue into Part B; Part B will enroll a separate cohort of participants. Part B will evaluate the efficacy of the selected ORJ-001 dose compared with placebo, with the primary efficacy endpoint being change from baseline in forced vital capacity (FVC) at Week 12. Secondary and exploratory assessments include percent predicted FVC, time to acute IPF exacerbation, respiratory hospitalization or death, patient-reported outcomes, pharmacokinetics, and biomarkers of fibrosis. Adults aged 40 years or older with confirmed IPF and adequate pulmonary function who are receiving stable antifibrotic standard-of-care therapy, or who have previously discontinued such therapy due to tolerability or lack of response, may be eligible to participate.

研究の種類

介入

入学 (推定)

95

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

    • Alabama
      • Birmingham、Alabama、アメリカ、35294
        • 募集
        • University of Alabama at Birmingham
        • 主任研究者:
          • Tejaswini Kulkarni, MD
    • Florida
      • Doral、Florida、アメリカ、33172
        • 募集
        • Innova Pharma Research, LLC
    • Pennsylvania
      • DuBois、Pennsylvania、アメリカ、15801
        • 募集
        • Clinical Research Associates of Central PA

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

40年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Key Inclusion Criteria:

  1. Male or female participants aged ≥ 40 years when signing informed consent
  2. Non-smoker or ex-smoker who has stopped smoking for > 6 months prior to signing informed consent
  3. Diagnosis of IPF, as defined by 2022 international guidelines and confirmed by centrally adjudicated finding of a definite or probable UIP pattern on HRCT of the chest. The HRCT may be performed at screening or, if available, a historical HRCT obtained within 12 months from screening may be submitted for central review
  4. FVC of at least 45% of the predicted value and a DLCO, corrected for the hemoglobin level, of at least 25% and no greater than 90% of the predicted value. Note: Each test (FVC and DLCO) may be repeated once after a minimum of 24 hours if the initial result is deemed unreliable by the investigator
  5. If receiving SOC antifibrotic therapy, participants must be on a stable regimen of a single approved therapy for at least 60 days prior to the screening visit. Participants who have discontinued SOC antifibrotic therapy due to tolerability or lack of response may be enrolled after at least 30 days of discontinuing the SOC antifibrotic therapy.
  6. Negative serum pregnancy test in women of childbearing potential at the screening visit

Key Exclusion Criteria:

  1. Participants who are treatment-naïve with respect to SOC antifibrotic therapies
  2. Women who are pregnant, nursing, or who plan to become pregnant while in the trial
  3. Major surgery (including joint surgery) within 8 weeks from screening, or planned major surgery within 4 months following randomization
  4. Presence of one or more significant concurrent medical conditions that may affect the outcome of the study per investigator judgement
  5. Participants with relevant airway obstruction, defined as pre bronchodilator forced expiratory volume in 1 second (FEV1)/ forced vital capacity (FVC) ratio < 0.7 at screening
  6. Lower respiratory tract infection requiring antibiotics within 4 weeks from screening, or during the screening period (may be rescreened following recovery)
  7. Acute IPF exacerbation within 3 months from screening, or during the screening period
  8. Receiving more than 15 mg per day of prednisone during screening

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
実験的:Part A: ORJ-001 400 mg

Participants receive ORJ-001 400 mg administered subcutaneously (SC) twice weekly (BIW) for 12 weeks. Randomization ratio: 3:1:1 (400 mg:200 mg:placebo).

ORJ-001 is a peptide agonist of β1 integrin administered by subcutaneous injection twice weekly. In Part A, dose levels are 200 mg and 400 mg. In Part B, a single dose level selected from Part A will be evaluated.

Matching placebo administered by subcutaneous injection twice weekly.

実験的:Part A: ORJ-001 200 mg

Participants receive ORJ-001 200 mg administered subcutaneously (SC) twice weekly (BIW) for 12 weeks. Randomization ratio: 3:1:1 (active:active:placebo).

ORJ-001 is a peptide agonist of β1 integrin administered by subcutaneous injection twice weekly. In Part A, dose levels are 200 mg and 400 mg. In Part B, a single dose level selected from Part A will be evaluated.

Matching placebo administered by subcutaneous injection twice weekly.

プラセボコンパレーター:Part A: Placebo

Participants receive matching placebo administered subcutaneously (SC) twice weekly (BIW) for 12 weeks.

Matching placebo administered by subcutaneous injection twice weekly.

実験的:Part B: ORJ-001 (Selected Dose)

Participants receive the ORJ-001 dose selected based on Part A safety, tolerability, pharmacokinetic, pharmacodynamic, and efficacy data, administered subcutaneously (SC) twice weekly (BIW) for 12 weeks. Participants are randomized 1:1 to ORJ-001 or placebo.

ORJ-001 is a peptide agonist of β1 integrin administered by subcutaneous injection twice weekly. In Part A, dose levels are 200 mg and 400 mg. In Part B, a single dose level selected from Part A will be evaluated.

Matching placebo administered by subcutaneous injection twice weekly.

プラセボコンパレーター:Part B: Placebo

Participants receive matching placebo administered subcutaneously (SC) twice weekly (BIW) for 12 weeks.

Matching placebo administered by subcutaneous injection twice weekly.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Part A: Safety and Tolerability of ORJ-001: Number of Participants with Treatment-Related Adverse Events (TEAEs)
時間枠:From first dose through Safety Follow-up Visit, up to 12 weeks.

Number of participants experiencing at least one treatment-emergent adverse event.

From first dose through Safety Follow-up Visit, up to 12 weeks.
Part A: Safety and Tolerability of ORJ-001: Severity of Treatment-Emergent Adverse Events (TEAEs)
時間枠:From first dose through Safety Follow-up Visit, up to 12 weeks.

Severity of treatment-emergent adverse events as graded according to CTCAE v6.0.

From first dose through Safety Follow-up Visit, up to 12 weeks.
Part A: Safety and Tolerability of ORJ-001: Change from Baseline in Systolic Blood Pressure
時間枠:Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.

Change from baseline in systolic blood pressure measured in millimeters of mercury (mmHg).

Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.
Part A: Safety and Tolerability of ORJ-001: Change from Baseline in Body Temperature
時間枠:Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.

Change from baseline in body temperature measured in degrees Celsius (°C).

Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.
Part A: Safety and Tolerability of ORJ-001: Change from Baseline in Heart Rate
時間枠:Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.

Change from baseline in heart rate measured in beats per minute (bpm).

Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.
Part A: Safety and Tolerability of ORJ-001: Change from Baseline in Respiratory Rate
時間枠:Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.

Change from baseline in respiratory rate measured in breaths per minute.

Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.
Part A: Safety and Tolerability of ORJ-001: Change from Baseline in Oxygen Saturation
時間枠:Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.

Change from baseline in oxygen saturation measured as percentage (% SpO₂).

Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.
Part A: Safety and Tolerability of ORJ-001: Change from Baseline in Corrected QT Interval
時間枠:Baseline, Week 4, Week 12, and Safety Follow-up Visit up to 12 weeks.

Change from baseline in corrected QT interval (QTc) measured by electrocardiogram (ECG) in milliseconds (ms).

Baseline, Week 4, Week 12, and Safety Follow-up Visit up to 12 weeks.
Part B: Change from Baseline in Forced Vital Capacity (FVC)
時間枠:Baseline to Week 12

Change from baseline in FVC measured by spirometry at Week 12.

Baseline to Week 12

二次結果の測定

結果測定
メジャーの説明
時間枠
Part B: Change From Baseline in Percent Predicted Forced Vital Capacity (FVC%)
時間枠:Baseline to Week 12.

Change from baseline in percentage of predicted FVC measured by spirometry at Week 12.

Baseline to Week 12.
Part B: Time to Acute Exacerbation of IPF, Hospitalization for a Respiratory Cause, or Death
時間枠:Up to Week 12.

Time, in days, to first occurrence of acute IPF exacerbation, hospitalization for a respiratory cause, or death.

Up to Week 12.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Oorja Bio Medical Director、Oorja Bio, Inc.

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年11月1日

一次修了 (推定)

2029年1月1日

研究の完了 (推定)

2029年3月1日

試験登録日

最初に提出

2026年9月21日

QC基準を満たした最初の提出物

2026年10月6日

最初の投稿 (実際)

2026年10月9日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月18日

QC基準を満たした最後の更新が送信されました

2026年11月16日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • ORJ-001-01

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する